Illumina Inc (ILMN)

Illumina stock (ILMN) has surged 82% in six months, driven by accelerating clinical sequencing demand and speculation about an S&P 500 promotion. Despite this impressive rally, the average Street price target of $199 remains 11% below its current price of $223.22. TIKR’s model suggests a more modest long-term return, valuing ILMN at $259 by late 2030, implying that much of the re-rating based on improved fundamentals has already been absorbed into the share price.

Illumina (ILMN) has secured a new US$1 billion unsecured revolving credit facility, replacing its previous agreement. This new facility offers updated covenants and increased flexibility, aiming to provide a liquidity backstop and support the company's capital structure. It allows Illumina to fund working capital and strategic projects, although the actual usage and impact on leverage will be monitored in future quarterly reports.

Illumina Inc. (ILMN) saw its stock rise by 1.74% to $223.22 on Monday, marking its fourth consecutive day of gains. This performance occurred during a mixed trading session where the Dow Jones Industrial Average increased, but the S&P 500 Index declined. The company's stock outperformed its competitors on this trading day.

Illumina director Keith A. Meister's affiliated funds, advised by Corvex Management LP, indirectly sold a total of 679,574 shares of Illumina common stock between August 19-21, 2026. These sales occurred at weighted average prices ranging from $201.59 to $220.43 per share. Despite these indirect sales, Mr. Meister still directly holds 6,780 shares of Illumina common stock.

Illumina director Keith Meister sold over $145 million worth of shares in Illumina, Inc. (NASDAQ:ILMN) through multiple transactions between August 19 and August 21, 2026. These sales, involving 683,474 shares, occurred as Illumina's stock surged 80% over the past year. The transactions were managed by Corvex Management LP, where Meister controls the general partner, and follow other recent company news including a $300 million note offering and positive analyst reactions to quarterly results.